All News

An expert explains what the FDA’s accelerated approval of Krazati means for patients with KRAS G12C-mutant locally advanced or metastatic non-small cell lung cancer and what he hopes will come next.

During this holiday season, lighting candles in remembrance and in honor of those who need a little light on their cancer journeys helps me cope, too.

As part of its Speaking Out video series, CURE® spoke with Michael J. Rovito, on behalf of the Testicular Cancer Foundation, about survivorship.

Treat yourself without the guilt! Here are three delicious — and most importantly nutritious — desserts to try at home when you are craving something sweet.

From updates on clinical trials to a podcast where an oncology nurse shares how her son’s leukemia diagnosis changed her life, here are CURE®’s top blood cancer articles from the year 2022.

After undergoing a mastectomy, women can either proceed with reconstruction or "go flat," but one expert says that the correct decision is what’s best for the patient.

As I work on a holiday drawing, the coyotes are howling outside, while inside, my cat and I are reminded of my wife who died of breast cancer.

CURE® surveyed its audience to see which terms they prefer using when describing their cancer experiences. Some people who have experienced cancer explained why they dislike certain labels.

HIF-2 alpha inhibitors are transforming therapy for patients with renal cell carcinoma and von Hippel-Lindau disease.

Take a look at the top advancements and most popular articles about kidney cancer from the year 2022.

As part of CURE®’s four-part gastrointestinal cancers webinar series, a panel of experts recently answered questions and offered advice around different types of testing.

Now that I’ve met my insurance premium, I’m scheduling some year-end cancer appointments, and praying for good results.

Biliary duct cancer, or cholangiocarcinoma, has always been known as a difficult-to-treat disease, but immunotherapies may make an impact on patients' lives.

The indication for Pemfexy has been approved to include patients with metastatic, non-squamous, non-small cell lung cancer without EGFR or ALK genomic tumor mutations.

Adults with graft-versus-host disease who were treated with a three-drug regimen with cyclophosphamide after transplant may have improved survival rate compared with those treated with a two-drug regimen.

Watch Dr. Aaron Gerds and Dr. Andrew Kuykendall answer questions about myelofibrosis during the CURE Educated Patient MPN Summit.

The breast cancer community is made up of men and women who understand the importance of camaraderie. By showing each other love and support, no one ever feels alone. 

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

This is the only first-line trial to show benefit with immuno-oncology plus chemotherapy in patients with advanced or recurrent endometrial cancer.

Adstiladrin represents the first gene therapy approved by the FDA for the treatment of patients with high-risk non-muscle invasive bladder cancer who are resistant to BCG, the first-line standard of care for these patients.

Women with multiple ipsilateral breast cancer may have similar recurrence-free outcomes with a lumpectomy as one might encounter with a mastectomy, opening the door for more surgical treatment options for these patients.

In my cousin Barbara’s salon, a group of fellow Black women helped boost my confidence as I shaved my head after being diagnosed with cancer.

Sponsored by AbbVie

From Tina Turner’s son, Ronnie, dying of cancer to the Miami Dolphins honoring a group of people who raised over $5 million for oncology care and research, here is what’s happening in the cancer space this week.

Men with obesity before starting prostate cancer treatment may have an increased risk for death from heart disease or any cause rather than from prostate cancer itself, study results showed.

Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

In honor of CURE®’s 20th anniversary, here is a roundup of some of the major advancements in the world of cancer care, according to experts, patients and advocates.

The treatment and support that children with cancer receive has advanced over the past 20 years, but more progress to improve the cure rate is on the horizon.

When I experienced a sarcoma recurrence in 2017, I was given less than a 10% chance to live for five years. Now that I’ve surpassed that statistic and celebrated my five-year wedding anniversary, I’ve proven to myself that I’m not defined by cancer statistics.

When Sean Korbitz was a 20-year-old college student, his life trajectory changed with a rare cancer diagnosis, resulting in the removal of 40 tumors; fifteen years later, a new drug made him feel like a “medical miracle.”